Do Oncogenes Determine Clinical Features in Chronic Myeloid Leukaemia?

Dreazen, O; Rassool, Feyruz V.; Rs, Sparkes; Klisak, Ivana; Goldman, J M; Gale, R P

doi:10.1016/s0140-6736(87)90594-0

Cited by 60 publications

(18 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Insertion of part of the abl gene in the bcr gene without reciprocal translocation to chromosome 9 has been described by Morris et al [46] and Dreazen et al [41].…”

Section: Molecular Investigations In Ph-negative CMLmentioning

confidence: 90%

“…The five exceptions with a BCR breakpoint were all reported by the same research group [41,42]. It would be interesting to reexamine the differential count and other clinical data to check if these patients really belong to the group of aCML or resemble more CML.…”

Section: Molecular Investigations In Ph-negative CMLmentioning

confidence: 90%

“…First, the different authors used clinical, hematologic and morphologic criteria that are not exactly the same, resulting in differences in diagnosis. Second, some authors [41,42] diagnosed BCR breakpoints on extra bands in only one out of several different restriction enzyme digests. In such cases, the occurrem:e of a restriction enzyme polynlorphism is a inore likely cause f()r the aberrant fragment than the l)reseo(:e of a BCR breakpoint.…”

Section: Molecular Investigations In Ph-negative CMLmentioning

confidence: 99%

See 2 more Smart Citations

Review of clinical, cytogenetic, and molecular aspects of Ph-negative CML

Plas

Grosveld

Hagemeijer

1991

Cancer Genetics and Cytogenetics

View full text Add to dashboard Cite

show abstract

“…Insertion of part of the abl gene in the bcr gene without reciprocal translocation to chromosome 9 has been described by Morris et al [46] and Dreazen et al [41].…”

Section: Molecular Investigations In Ph-negative CMLmentioning

confidence: 90%

Section: Molecular Investigations In Ph-negative CMLmentioning

confidence: 90%

Section: Molecular Investigations In Ph-negative CMLmentioning

confidence: 99%

See 1 more Smart Citation

Review of clinical, cytogenetic, and molecular aspects of Ph-negative CML

Plas

Grosveld

Hagemeijer

1991

Cancer Genetics and Cytogenetics

View full text Add to dashboard Cite

show abstract

“…Moreover, Wiedemann et al [10] disclosed that all cases that have bcr rearrange ment, showed P210 bcr abl. On the other hand, Dreasen et al [5] reported the opposite findings obtained from the analysis of 10 cases of Ph-negative CML.…”

Section: Discussionmentioning

confidence: 91%

“…Recently, with the development of a diagnostic criteria based on the morphological classification [3] and with the elucidation of the mo lecular background of Ph translocation [4], the con cept of Ph-negative CML has changed fundamen tally. Although some controversy still remains [5], the current concept of Ph-negative CML is that without apparent cytogenetic changes, the same molecular event can exist as Ph-positive CML and that the clini cal and the hematological features of the chronic phase are also identical to those in Ph-positive disease [6][7][8][9][10], However, the subsequent clinical course of Phnegative CML is still unknown. Only a few cases of Ph-negative CML that developed lymphoid blast cri sis have been previously reported [11][12][13][14].…”

Section: Introductionmentioning

confidence: 99%

Lymphoid Blast Crisis in a Patient with Philadelphia-Chromosome-Negative Chronic Myelocytic Leukemia

Takahira

Shibata²,

Hirata³

et al. 1989

Acta Haematol

View full text Add to dashboard Cite

A 24-year-old man with Philadelphia-chromosome (Ph)-negative chronic myelocytic leukemia (CML) developed lymphoid blast crisis. In the chronic phase, karyotype was normal and the clinical and hematological features were indistinguishable from those of Ph-positive CML. Rearrangement of the breakpoint cluster region (bcr) was observed. In the blast phase, blast cells showed early B-cell phenotype (CALLA +, Ia +, TdT+) with a rearranged immunoglobulin heavy-chain gene joining region (JH). By using an immuno-blotting method and antiphosphotyrosine sera, P210^bcr-ab1 protein was detected. The patient responded well to vincristine and prednisolone (VP) therapy. These findings support the concept that Ph-negative bcr + CML can behave in a very similar fashion to Ph-positive CML, not only in the clinical features of the chronic phase but also in the manner of the blast crisis.

show abstract

Philadelphia chromosome-negative chronic myelogenous leukemia with rearrangement of the breakpoint cluster region. Long term follow-up results

Cortes

Talpaz

Beran

et al. 1995

Cancer

View full text Add to dashboard Cite

Background. Five to 10% of patients with chronic myelogenous leukemia (CML) do not have the Philadelphia chromosome (Ph), but one‐third of them have rearrangements of the breakpoint cluster region (BCR‐positive). Methods. The authors analyzed the characteristics, treatment response, and prognosis of 23 patients with BCR‐positive, Ph‐negative CML, and compared them with patients with Ph‐positive CML, Ph‐negative BCR‐negative CML and chronic myelomonocytic leukemia (CMML) treated during the same period. Results. Seventeen patients had early chronic phase CML, 3 had late chronic phase, 2 had accelerated phase, and 1 had blastic phase. The median age was 44 years (range, 14‐71 years), median platelet count was 402 × 109/l, and median leukocyte count was 86 × 109/l. Fourteen of the 17 patients with early chronic phase CML received alpha‐interferon; 12 (86%) achieved complete hematologic remission. Median survival in chronic phase CML was 60 months (range, 3‐90+ months). Patients with Ph‐negative BCR‐positive CML and those with Ph‐positive CML had similar characteristics and outcome. Compared with patients with Ph‐negative BCR‐negative CML and CMML, patients with Ph‐negative BCR‐positive CML and Ph‐positive CML were significantly younger, had a significantly higher incidence of leukocytosis, thrombocytosis, and peripheral and marrow basophilia, and a significantly lower incidence of anemia, thrombocytopenia, marrow blast percent, and peripheral and marrow monocytosis. The median survival was 60 months for Ph‐negative BCR‐positive CML, 73 months for Ph‐positive CML, 25 months for Ph‐negative BCR‐negative CML, and 9 months for CMML (P < 0.001). When analyzed adjusting for their stage, patients classified with Ph‐negative BCR‐positive CML Stage I disease had a significantly better survival than did patients with Ph‐negative BCR‐negative CML (P < 0.02). Conclusions. Patients with Ph‐negative BCR‐positive CML are similar to those with Ph‐positive CML and should be treated with the same approaches. Cancer 1995;75:464‐70.

show abstract

Do Oncogenes Determine Clinical Features in Chronic Myeloid Leukaemia?

Cited by 60 publications

References 19 publications

Review of clinical, cytogenetic, and molecular aspects of Ph-negative CML

Review of clinical, cytogenetic, and molecular aspects of Ph-negative CML

Lymphoid Blast Crisis in a Patient with Philadelphia-Chromosome-Negative Chronic Myelocytic Leukemia

Philadelphia chromosome-negative chronic myelogenous leukemia with rearrangement of the breakpoint cluster region. Long term follow-up results

Contact Info

Product

Resources

About